Anika Therapeutics Blows Past Q2 Earnings Estimates

Anika Therapeutics (NASDAQ: ANIK) reported solid improvement when it announced its second-quarter results in May. Revenue increased by 16% year over year while earnings were up by $4.5 million, or $0.31 per diluted share -- much better than the loss of $6.7 million, or $0.46 per diluted share, it had in the prior-year period.